Calcium-Activated-Calcineurin Reduces the In Vitro and In Vivo Sensitivity of Fluconazole to Candida albicans via Rta2p

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Jia, Yu ^a,b   Tang, Ren Jie ^a   Wang, Lin ^a   Zhang, Xiang ^b   Wang, Ying ^c   Jia, Xin Ming ^b   Jiang, Yuan Ying ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCIUM ACTIVATED CALCINEURIN; CALCIUM ION; CASPOFUNGIN; FLUCONAZOLE; PLACEBO; PROTEIN; PROTEIN RTA2P; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CALCIUM SIGNALING; CANDIDA ALBICANS; CELL MEMBRANE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FUNGAL STRAIN; FUNGAL VIRULENCE; GENE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; MOUSE; NONHUMAN; PATHOGEN LOAD; PROTEIN EXPRESSION; PROTEIN TARGETING; RTA2 GENE; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; ANTIFUNGAL AGENTS; CALCINEURIN; CALCIUM; CANDIDA ALBICANS; CANDIDEMIA; CELL MEMBRANE; DRUG RESISTANCE, FUNGAL; ENZYME ACTIVATION; FEMALE; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; MICE;

CANDIDA ALBICANS; MAMMALIA; MURINAE;

EID: 84868109141     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048369     Document Type: Article

References (57)

1. Schelenz S, Abdallah S, Gray G, Stubbings H, Gow I, et al. (2011) Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors. J Oral Pathol Med 40: 83-89.
2. Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L, (2010) Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev 24: 51-61.
3. Zaoutis T, (2010) Candidemia in children. Curr Med Res Opin 26: 1761-1768.
4. Ortega M, Marco F, Soriano A, Almela M, Martinez J, et al. (2011) Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect 77: 157-161.
5. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, et al. (2011) Epidemiology, Species Distribution, Antifungal Susceptibility and Outcome of Nosocomial Candidemia in a Tertiary Care Hospital in Italy. PLoS One 6: e24198.
6. Jutiamornlerd N, Chusri S, Siripaitoon P, (2011) Epidemiology of Candidemia in Songklanagarind Hospital. J Med Assoc Thai 94: 927-932.
7. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, et al. (2002) The direct cost and incidence of systemic fungal infections. Value Health 5: 26-34.
8. Hassan I, Powell G, Sidhu M, Hart W, Denning D, (2009) Excess mortality, length of stay and cost attributable to candidaemia. J Infect 59: 360-365.
9. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, et al. (2009) Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48: 1695-1703.
10. Cortes JA, Reyes P, Gómez C, Buitrago G, Leal AL, (2011) Fungal bloodstream infections in tertiary care hospitals in Colombia. Rev Iberoam Micol 28: 74-78.
11. Cowen LE, (2008) The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat Rev Microbiol 6: 187-198.
12. Chapman SW, Sullivan DC, Cleary JD, (2008) In search of the holy grail of antifungal therapy. Trans Am Clin Climatol Assoc 119: 197-215.
13. Sionov E, Chang YC, Garraffo HM, Dolan MA, Ghannoum MA, et al. (2012) Identification of a Cryptococcus neoformans Cytochrome P450 Lanosterol 14α-Demethylase (Erg11) Residue Critical for Differential Susceptibility between Fluconazole/Voriconazole and Itraconazole/Posaconazole. Antimicrob Agents Chemother 56: 1162-1169.
14. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, et al. (2009) Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 22: 291-321.
15. Traeder C, Kowoll S, Arastéh K, (2008) Candida infection in HIV positive patients 1985-2007. Mycoses 51: 58-61.
16. Steinbach WJ, Reedy JL, Cramer RA, Perfect JR, Heitman J, (2007) Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 5: 418-430.
17. Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, et al. (2009) Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS pathogens 5: e1000532.
18. Sanglard D, Ischer F, Marchetti O, Entenza J, Bille J, (2003) Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol 48: 959-976.
19. Cowen LE, Lindquist S, (2005) Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309: 2185-2189.
20. Hoon S, Smith AM, Wallace IM, Suresh S, Miranda M, et al. (2008) An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol 4: 498-506.
21. Cowen LE, Singh SD, K hlerJR, Collins C, Zaas AK, et al. (2009) Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A 106: 2818-2823.
22. Jia XM, Wang Y, Jia Y, Gao PH, Xu YG, et al. (2009) RTA2 is involved in calcineurin-mediated azole resistance and sphingoid long-chain base release in Candida albicans. Cell Mol Life Sci 66: 122-134.
23. Karababa M, Valentino E, Pardini G, Coste AT, Bille J, et al. (2006) CRZ1, a target of the calcineurin pathway in Candida albicans. Mol Microbiol 59: 1429-1451.
24. Blankenship JR, Wormley FL, Boyce MK, Schell WA, Filler SG, et al. (2003) Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryot Cell 2: 422-430.
25. Bader T, Bodendorfer B, Schroppel K, Morschhauser J, (2003) Calcineurin is essential for virulence in Candida albicans. Infect Immun 71: 5344-5354.
26. Moore EW, (1970) Ionized calcium in normal serum, ultrafiltrates, and whole blood determined by ion-exchange electrodes. J Clin Invest 49: 318-334.
27. Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, et al. (2005) Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 43: 5848-5859.
28. Cruz MC, Goldstein AL, Blankenship JR, Del Poeta M, Davis D, et al. (2002) Calcineurin is essential for survival during membrane stress in Candida albicans. Embo J 21: 546-559.
29. Sun S, Li Y, Guo Q, Shi C, Yu J, et al. (2008) In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. Antimicrob Agents Chemother 52: 409-417.
30. Gamarra S, Rocha EMF, Zhang YQ, Park S, Rao R, et al. (2010) Mechanism of the synergistic effect of amiodarone and fluconazole in Candida albicans. Antimicrob Agents Chemother 54: 1753-1761.
31. Zhang YQ, Gamarra S, Garcia-Effron G, Park S, Perlin DS, et al. (2010) Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs. PLoS pathogens 6: e1000939.
32. Epp E, Vanier G, Harcus D, Lee AY, Jansen G, et al. (2010) Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence. PLoS Pathog 6: e1000753.
33. Cowen LE, (2009) Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathog 5: e1000471.
34. Hameed S, Dhamgaye S, Singh A, Goswami SK, Prasad R, (2011) Calcineurin signaling and membrane lipid homeostasis regulates iron mediated multidrug resistance mechanisms in Candida albicans. PLoS One 6: e18684.
35. Marchetti O, Entenza JM, Sanglard D, Bille J, Glauser MP, et al. (2000) Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother 44: 2932-2938.
36. Onyewu C, Afshari NA, Heitman J (2006) Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. Antimicrob Agents Chemother: 3963-3965.
37. Wang L, Jia Y, Tang RJ, Xu Z, Cao YB, et al. (2012) Proteomic Analysis of Rta2p-Dependent Raft-Association of Detergent-Resistant Membranes in Candida albicans. PLoS One 7: e37768.
38. Lee MCS, Hamamoto S, Schekman R, (2002) Ceramide biosynthesis is required for the formation of the oligomeric H+-ATPase Pma1p in the yeast endoplasmic reticulum. J Biol Chem 277: 22395-22401.
39. Gaigg B, Timischl B, Corbino L, Schneiter R, (2005) Synthesis of sphingolipids with very long chain fatty acids but not ergosterol is required for routing of newly synthesized plasma membrane ATPase to the cell surface of yeast. J Biol Chem 280: 22515-22522.
40. Gaigg B, Toulmay A, Schneiter R, (2006) Very long-chain fatty acid-containing lipids rather than sphingolipids per se are required for raft association and stable surface transport of newly synthesized plasma membrane ATPase in yeast. J Biol Chem 281: 34135-34145.
41. Mulet JM, Martin DE, Loewith R, Hall MN, (2006) Mutual antagonism of target of rapamycin and calcineurin signaling. Journal of Biological Chemistry 281: 33000-33007.
42. Aronova S, Wedaman K, Aronov PA, Fontes K, Ramos K, et al. (2008) Regulation of ceramide biosynthesis by TOR complex 2. Cell metabolism 7: 148-158.
43. Odabasi Z, Paetznick V, Rex JH, Ostrosky-Zeichner L, (2007) Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 51: 4214-4216.
44. Yang YL, Lin YH, Tsao MY, Chen CG, Shih HI, et al. (2006) Serum repressing efflux pump CDR1 in Candida albicans. BMC Mol Biol 7: 22.
45. Nakayama H, Tanabe K, Bard M, Hodgson W, Wu S, et al. (2007) The Candida glabrata putative sterol transporter gene CgAUS1 protects cells against azoles in the presence of serum. J Antimicrob Chemother 60: 1264-1272.
46. Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, et al. (2007) Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 51: 2253-2256.
47. Edlind T, Smith L, Henry K, Katiyar S, Nickels J, (2002) Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbiol 46: 257-268.
48. Withee JL, Mulholland J, Jeng R, Cyert MS, (1997) An essential role of the yeast pheromone-induced Ca2+ signal is to activate calcineurin. Mol Biol Cell 8: 263-277.
49. Galgiani JM, Standards NCfCL (1997) Reference method for broth dilution antifungal susceptibility testing yeast: approved standard: National Committee for Clinical Laboratory Standards.
50. Kawaai H, Seino H, Yamazaki S, Taki K, (2009) Changes in leukocyte migration during carbonic anhydrase activity inhibition. Burns 35: 397-404.
51. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, et al. (1997) Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 24: 235-247.
52. White TC, Marr KA, Bowden RA, (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11: 382-402.
53. Sanglard D, Ischer F, Monod M, Bille J, (1996) Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 40: 2300-2305.
54. Feng Q, Summers E, Guo B, Fink G, (1999) Ras Signaling Is Required for Serum-Induced Hyphal Differentiation in Candida albicans. J Bacteriol 181: 6339-63469.
55. Negredo A, Monteoliva L, Gil C, Pla J, Nombela C, (1997) Cloning, analysis and one-step disruption of the ARG5,6 gene of Candida albicans. Microbiology 143 (Pt 2): 297-302.
56. Fonzi WA, Irwin MY, (1993) Isogenic strain construction and gene mapping in Candida albicans. Genetics 134: 717-728.
57. Jia X, Ma Z, Jia Y, Gao P, Zhang J, et al. (2008) RTA2, a novel gene involved in azole resistance in Candida albicans. Biochem Biophys Res Commun 373: 631-636.